Literature DB >> 2378357

Visceral pathology of hereditary tyrosinemia type I.

P Russo1, S O'Regan.   

Abstract

The major pathological findings in 23 patients with hereditary tyrosinemia type I seen at the Hôpital Sainte-Justine over a 23-year period are reviewed in combination with findings in the literature. Hepatic and renal alterations are given special emphasis. Hepatic changes differ in the acute and chronic forms of the disease. The former is characterized by alterations shared by several hepatopathies of infancy, whereas the latter is characterized by established cirrhosis, frequently of a mixed macro- and micronodular type, with a frightening propensity for the development of hepatocellular carcinoma. Renal changes reflect tubular injury, resulting in Fanconi syndrome, with tubular dilatation, nephrocalcinosis, and involution of epithelial cells. A significant proportion of patients also reveal some degree of glomerulosclerosis and interstitial fibrosis, indicating at least the need for careful assessment and follow-up of renal function, particularly in light of the adverse renal effects of immunosuppressive regimens used in liver transplantation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2378357      PMCID: PMC1683701     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  39 in total

1.  Low incidence of glomerulosclerosis in normal kidneys.

Authors:  S M Smith; W E Hoy; L Cobb
Journal:  Arch Pathol Lab Med       Date:  1989-11       Impact factor: 5.534

2.  Experience of the Manitoba Perinatal Screening Program, 1965-85.

Authors:  J G Fox
Journal:  CMAJ       Date:  1987-11-15       Impact factor: 8.262

3.  Liver disorders in children: the indications for liver replacement in parenchymal and metabolic diseases.

Authors:  A P Mowat
Journal:  Transplant Proc       Date:  1987-08       Impact factor: 1.066

4.  Tyrosinaemia type I and hypertrophic obstructive cardiomyopathy.

Authors:  M A Edwards; A Green; A Colli; G Rylance
Journal:  Lancet       Date:  1987-06-20       Impact factor: 79.321

5.  Hereditary tyrosinemia type I (chronic form): pathologic findings in the liver.

Authors:  L P Dehner; D C Snover; H L Sharp; N Ascher; R Nakhleh; D L Day
Journal:  Hum Pathol       Date:  1989-02       Impact factor: 3.466

6.  Hereditary tyrosinemias (type I): a new vista on tyrosine toxicity and cancer.

Authors:  C Laberge; A Lescault; R M Tanguay
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

7.  Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation.

Authors:  M Tuchman; D K Freese; H L Sharp; M L Ramnaraine; N Ascher; J R Bloomer
Journal:  J Pediatr       Date:  1987-03       Impact factor: 4.406

8.  Effect of dietary treatment on the renal tubular function in a patient with hereditary tyrosinemia.

Authors:  Y Suzuki; M Konda; I Imai; H Imamura; S Shimao; T Okaka
Journal:  Int J Pediatr Nephrol       Date:  1987 Jul-Sep

Review 9.  Hereditary tyrosinemia type I--an overview.

Authors:  E A Kvittingen
Journal:  Scand J Clin Lab Invest Suppl       Date:  1986

10.  Serial decrease in glomerular filtration rate in long-term pediatric liver transplantation survivors treated with cyclosporine.

Authors:  S V McDiarmid; R B Ettenger; R N Fine; R W Busuttil; M E Ament
Journal:  Transplantation       Date:  1989-02       Impact factor: 4.939

View more
  28 in total

1.  Hereditary tyrosinemia type 1 from a single center in Egypt: clinical study of 22 cases.

Authors:  Hanaa El-Karaksy; Mona Fahmy; Mona El-Raziky; Nehal El-Koofy; Rokaya El-Sayed; Mohamed S Rashed; Hasan El-Kiki; Ahmad El-Hennawy; Nabil Mohsen
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

2.  Single dose NTBC-treatment of hereditary tyrosinemia type I.

Authors:  A Schlune; E Thimm; D Herebian; U Spiekerkoetter
Journal:  J Inherit Metab Dis       Date:  2012-02-04       Impact factor: 4.982

3.  Efficient production of Fah-null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer.

Authors:  Raymond D Hickey; Joseph B Lillegard; James E Fisher; Travis J McKenzie; Sean E Hofherr; Milton J Finegold; Scott L Nyberg; Markus Grompe
Journal:  Hepatology       Date:  2011-08-09       Impact factor: 17.425

Review 4.  Liver repopulation for the treatment of metabolic diseases.

Authors:  M Grompe
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

5.  The crystal structures of Zea mays and Arabidopsis 4-hydroxyphenylpyruvate dioxygenase.

Authors:  Iris M Fritze; Lars Linden; Jörg Freigang; Günter Auerbach; Robert Huber; Stefan Steinbacher
Journal:  Plant Physiol       Date:  2004-04       Impact factor: 8.340

6.  Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1.

Authors:  Raymond D Hickey; Shennen A Mao; Jaime Glorioso; Faysal Elgilani; Bruce Amiot; Harvey Chen; Piero Rinaldo; Ronald Marler; Huailei Jiang; Timothy R DeGrado; Lukkana Suksanpaisan; Michael K O'Connor; Brittany L Freeman; Samar H Ibrahim; Kah Whye Peng; Cary O Harding; Chak-Sum Ho; Markus Grompe; Yasuhiro Ikeda; Joseph B Lillegard; Stephen J Russell; Scott L Nyberg
Journal:  Sci Transl Med       Date:  2016-07-27       Impact factor: 17.956

7.  Mice deficient in glutathione transferase zeta/maleylacetoacetate isomerase exhibit a range of pathological changes and elevated expression of alpha, mu, and pi class glutathione transferases.

Authors:  Cindy E L Lim; Klaus I Matthaei; Anneke C Blackburn; Richard P Davis; Jane E Dahlstrom; Mark E Koina; M W Anders; Philip G Board
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

8.  Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.

Authors:  D Phaneuf; M Lambert; R Laframboise; G Mitchell; F Lettre; R M Tanguay
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

9.  Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.

Authors:  Caitlin VanLith; Rebekah Guthman; Clara T Nicolas; Kari Allen; Zeji Du; Dong Jin Joo; Scott L Nyberg; Joseph B Lillegard; Raymond D Hickey
Journal:  Hum Gene Ther       Date:  2018-06-22       Impact factor: 5.695

10.  NTBC treatment in tyrosinaemia type I: long-term outcome in French patients.

Authors:  A Masurel-Paulet; J Poggi-Bach; M-O Rolland; O Bernard; N Guffon; D Dobbelaere; J Sarles; H Ogier de Baulny; G Touati
Journal:  J Inherit Metab Dis       Date:  2008-01-25       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.